Dosage protocol · Healing & Recovery
KLOW 80 mg
Component concentrations: TB-500, BPC-157, KPV each at ~3.33 mg/mL; GHK-Cu at ~16.7 mg/mL.
- Reconstitute: Add 3.0 mL bacteriostatic water → ~26.7 mg/mL total concentration.
- Component concentrations: TB-500, BPC-157, KPV each at ~3.33 mg/mL; GHK-Cu at ~16.7 mg/mL.
- Easy measuring: At 26.7 mg/mL total, 1 unit = 0.01 mL ≈ 267 mcg total peptide on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
BAC water3.0mL
Concentration26.7mg/mL
Reconstitution
KLOW dosage chart
KLOW dosage chart
| Week | Dose | Draw | |||
|---|---|---|---|---|---|
| Weeks 1–2 | TB-500: 250 mcg \ | BPC-157: 250 mcg \ | KPV: 250 mcg \ | GHK-Cu: 1.25 mg | 7.5 units (0.075 mL) |
| Weeks 3–4 | TB-500: 500 mcg \ | BPC-157: 500 mcg \ | KPV: 500 mcg \ | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
| Weeks 5–8 | TB-500: 750 mcg \ | BPC-157: 750 mcg \ | KPV: 750 mcg \ | GHK-Cu: 3.75 mg | 22.5 units (0.225 mL) |
| Weeks 9–12 (Maintenance) | TB-500: 500 mcg \ | BPC-157: 500 mcg \ | KPV: 500 mcg \ | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
KLOW is not a single molecule with its own chemical identity. It is an informal name for a peptide blend, typically combining four separately studied research compounds: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic gastric pentadecapeptide), TB-500 or thymosin beta-4-related material (linked to actin and cell-migration biology), and KPV (a tripeptide derived from the tail end of alpha-melanocyte-stimulating hormone).
Because KLOW describes a combination rather than one approved product, there is no single manufacturing standard, official monograph, or unified safety record behind the name. Evidence has to be evaluated on two separate levels: what is known about each individual component, and what is known — usually much less — about the combined mixture people actually buy or use under the KLOW label.
Benefits & side effects
No dedicated clinical trials of the combined KLOW formulation appear in public trial registries or peer-reviewed literature; the evidence that exists is component-specific. GHK-Cu has the most developed literature, including some clinically oriented dermatology research.[5] Thymosin beta-4 has been studied in wound-healing contexts, while BPC-157 and KPV research remains largely preclinical — animal, cell, or tissue-model work rather than large controlled human trials.
Evidence for one ingredient cannot be transferred to another, and evidence for individual ingredients cannot be transferred to the blend as a whole. Claims about inflammation control, tissue regeneration, or injury recovery attributed to KLOW are, at best, extrapolated from separate component studies, not confirmed for the mixture itself.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.
1
Reconstitution
mg
mL
Concentration—
Per unit (0.01 mL)—
Per 10 units (0.1 mL)—
2
Your dose
Doses per vial—
Vial lasts—
Draw to
— units
=
—